Clomifene citrate CAS:50-41-9 is the citrate salt form of clomiphene, a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues. This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation.
Clomifene citrate CAS:50-41-9 has been the most widely used treatment for fertility enhancement for the past 40 years. Clomiphene was a revolutionary advance in reproductive medicine and quickly became popular for induction of ovulation because of its ease of administration and minimal side effects. However, letrozole, an aromatase inhibitor, is also effective for ovulation induction in women with polycystic ovary syndrome (PCOS).
Clomifene citrate CAS:50-41-9 could be supplied in different size with competitive price.